Advances in molecular pathogenesis and treatment of intrahepatic cholangiocarcinoma

VernacularTitle:肝内胆管癌发病机制及治疗相关进展
Author: Tian PU ¹ ; Qiang FANG ; Zixiang CHEN ; Ming CAI ; Dong JIANG ; Xiaoping GENG ; Fubao LIU
Author Information

1. 安徽医科大学第一附属医院普通外科，合肥　230032
From: Chinese Journal of Digestive Surgery 2020;19(6):697-702
CountryChina
Language:Chinese
Abstract: Intrahepatic cholangiocarcinoma (ICC) is a group of adenocarcinoma that derives from epithelium of the subbranches of intrahepatic bile ducts, which is characterized by difficulty in early diagnosis, high malignancy and poor prognosis. ICC is relatively rare, but it is the second most common in primary liver cancer, and its incidence has gradually increased worldwide. Radical resection is recognized as the only treatment that can bring better long-term survival currently. However, many surgery-related problems, such as lymph node dissection and major vascular resection and reconstruction, are still controversial. Adjuvant therapy, including chemotherapy, regional therapy, targeted therapy and immunotherapy, has received increasing attention in recent years. Although there is no uniform standard, a large number of related studies have supported its efficacy. In this article, the authors have reviewed the molecular pathogenesis of ICC and advances in treatment.